Director at C4 Therapeutics (NASDAQ: CCCC) takes stock pay

Rhea-AI Filing Summary

GROGAN DONNA ROY reported acquisition or exercise transactions in this Form 4 filing.

C4 Therapeutics director Donna Roy Grogan received 5,370 shares of common stock as compensation. The shares were issued under the company’s Non-Employee Director Compensation Policy, where she elected stock instead of cash fees for board service.

The value was based on the closing market price of $2.70 per share on April 1, 2026. After this grant, she directly holds 71,512 shares of C4 Therapeutics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GROGAN DONNA ROY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,370	$2.70	$14K

Holdings After Transaction: Common Stock — 71,512 shares (Direct)

Footnotes (1)

1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2026.

Key Figures

Shares granted: 5,370 shares Reference share price: $2.70 per share Shares held after grant: 71,512 shares

3 metrics

Shares granted 5,370 shares Common stock award on April 1, 2026

Reference share price $2.70 per share Closing market price on April 1, 2026

Shares held after grant 71,512 shares Total direct holdings after transaction

Key Terms

Non-Employee Director Compensation Policy, common stock, closing market price

3 terms

Non-Employee Director Compensation Policy financial

"issued in accordance with the Issuer's Non-Employee Director Compensation Policy"

common stock financial

"receive shares of the Issuer's common stock in lieu of cash compensation"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

closing market price financial

"based upon the closing market price of the Issuer's common stock on April 1, 2026"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GROGAN DONNA ROY

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A(1)		5,370	A	$2.7(2)	71,512	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2026.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did C4 Therapeutics (CCCC) report for Donna Roy Grogan?

C4 Therapeutics reported that director Donna Roy Grogan received 5,370 shares of common stock. The shares are a stock-based fee for her board service, issued instead of cash under the company’s Non-Employee Director Compensation Policy on April 1, 2026.

Was the C4 Therapeutics (CCCC) insider transaction a purchase or a grant?

The transaction was a grant, not an open-market purchase. Donna Roy Grogan acquired 5,370 shares as a stock award in lieu of cash compensation, consistent with the company’s Non-Employee Director Compensation Policy for non-employee directors of C4 Therapeutics.

At what price was the C4 Therapeutics (CCCC) stock grant valued for Donna Roy Grogan?

The grant was valued using a price of $2.70 per share. This price reflects the closing market price of C4 Therapeutics common stock on April 1, 2026, as disclosed, and serves only as the reference value for the director compensation award.

How many C4 Therapeutics (CCCC) shares does Donna Roy Grogan hold after this Form 4 transaction?

After the grant, Donna Roy Grogan directly holds 71,512 shares of C4 Therapeutics common stock. This total includes the newly issued 5,370 shares received as non-cash director compensation under the company’s Non-Employee Director Compensation Policy for board members.

Why did C4 Therapeutics (CCCC) issue shares instead of cash to Donna Roy Grogan?

Shares were issued under C4 Therapeutics’ Non-Employee Director Compensation Policy. That policy allows a non-employee director like Donna Roy Grogan to elect to receive common stock instead of cash fees for board service, aligning director compensation partly with shareholder interests.